Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00512714 | Endometrium | AEH | negative regulation of cellular component movement | 68/2100 | 367/18723 | 2.06e-05 | 4.11e-04 | 68 |
GO:002240714 | Endometrium | AEH | regulation of cell-cell adhesion | 79/2100 | 448/18723 | 2.90e-05 | 5.40e-04 | 79 |
GO:00068988 | Endometrium | AEH | receptor-mediated endocytosis | 49/2100 | 244/18723 | 3.54e-05 | 6.24e-04 | 49 |
GO:004521610 | Endometrium | AEH | cell-cell junction organization | 42/2100 | 200/18723 | 4.26e-05 | 7.20e-04 | 42 |
GO:00310997 | Endometrium | AEH | regeneration | 41/2100 | 198/18723 | 7.29e-05 | 1.11e-03 | 41 |
GO:00426925 | Endometrium | AEH | muscle cell differentiation | 68/2100 | 384/18723 | 8.88e-05 | 1.30e-03 | 68 |
GO:00075967 | Endometrium | AEH | blood coagulation | 43/2100 | 217/18723 | 1.42e-04 | 1.89e-03 | 43 |
GO:00431128 | Endometrium | AEH | receptor metabolic process | 35/2100 | 166/18723 | 1.64e-04 | 2.15e-03 | 35 |
GO:00075997 | Endometrium | AEH | hemostasis | 43/2100 | 222/18723 | 2.39e-04 | 2.86e-03 | 43 |
GO:00508177 | Endometrium | AEH | coagulation | 43/2100 | 222/18723 | 2.39e-04 | 2.86e-03 | 43 |
GO:00509008 | Endometrium | AEH | leukocyte migration | 64/2100 | 369/18723 | 2.57e-04 | 3.04e-03 | 64 |
GO:00316237 | Endometrium | AEH | receptor internalization | 26/2100 | 113/18723 | 2.62e-04 | 3.08e-03 | 26 |
GO:007052710 | Endometrium | AEH | platelet aggregation | 18/2100 | 67/18723 | 3.09e-04 | 3.48e-03 | 18 |
GO:00511465 | Endometrium | AEH | striated muscle cell differentiation | 51/2100 | 283/18723 | 4.20e-04 | 4.46e-03 | 51 |
GO:005087815 | Endometrium | AEH | regulation of body fluid levels | 64/2100 | 379/18723 | 5.40e-04 | 5.44e-03 | 64 |
GO:000704310 | Endometrium | AEH | cell-cell junction assembly | 30/2100 | 146/18723 | 7.29e-04 | 6.98e-03 | 30 |
GO:00011017 | Endometrium | AEH | response to acid chemical | 28/2100 | 135/18723 | 9.24e-04 | 8.43e-03 | 28 |
GO:00026858 | Endometrium | AEH | regulation of leukocyte migration | 39/2100 | 210/18723 | 1.06e-03 | 9.33e-03 | 39 |
GO:190303410 | Endometrium | AEH | regulation of response to wounding | 32/2100 | 167/18723 | 1.69e-03 | 1.36e-02 | 32 |
GO:00610419 | Endometrium | AEH | regulation of wound healing | 27/2100 | 134/18723 | 1.77e-03 | 1.41e-02 | 27 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CD9 | SNV | Missense_Mutation | novel | c.361G>T | p.Val121Phe | p.V121F | P21926 | protein_coding | deleterious(0.01) | possibly_damaging(0.649) | TCGA-A8-A07U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD |
CD9 | SNV | Missense_Mutation | | c.8N>A | p.Val3Asp | p.V3D | P21926 | protein_coding | deleterious(0.04) | possibly_damaging(0.723) | TCGA-AO-A124-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
CD9 | SNV | Missense_Mutation | | c.286C>A | p.Leu96Ile | p.L96I | P21926 | protein_coding | deleterious(0.03) | probably_damaging(0.936) | TCGA-EW-A1P8-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | fluorouracil | PD |
CD9 | insertion | Nonsense_Mutation | novel | c.481_482insCTCACTAACCAGGCTGGTCTTGAACTCCTGGTCTCAAG | p.Gln161ProfsTer3 | p.Q161Pfs*3 | P21926 | protein_coding | | | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
CD9 | insertion | Nonsense_Mutation | novel | c.363_364insTCGAGGACCACGTTTGCTTTTTTTCCCTGAATCCA | p.Gln122SerfsTer10 | p.Q122Sfs*10 | P21926 | protein_coding | | | TCGA-A8-A07U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD |
CD9 | SNV | Missense_Mutation | rs146304211 | c.664N>T | p.Arg222Cys | p.R222C | P21926 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AA-A01R-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | PD |
CD9 | SNV | Missense_Mutation | rs777932393 | c.679N>G | p.Met227Val | p.M227V | P21926 | protein_coding | tolerated(0.94) | benign(0.001) | TCGA-AY-6197-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CD9 | SNV | Missense_Mutation | | c.142N>C | p.Glu48Gln | p.E48Q | P21926 | protein_coding | tolerated(0.1) | possibly_damaging(0.557) | TCGA-G4-6294-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | fluorouracil | PD |
CD9 | SNV | Missense_Mutation | novel | c.446N>T | p.Ala149Val | p.A149V | P21926 | protein_coding | tolerated(0.18) | possibly_damaging(0.87) | TCGA-AJ-A3BH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
CD9 | SNV | Missense_Mutation | | c.199N>A | p.Gly67Ser | p.G67S | P21926 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-AP-A0LG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
928 | CD9 | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | | PROPIONIBACTERIUM ACNES | | 15902693 |
928 | CD9 | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | | EOTAXIN | | 10704064 |
928 | CD9 | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | | TYROSINE KINASE INHIBITOR | | 7592610 |
928 | CD9 | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | | ANDROGENS | | 16128989 |
928 | CD9 | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | | INTERLEUKIN-16 | | 16144798 |
928 | CD9 | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | | IL-5 | | 10704064 |
928 | CD9 | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | | STEROID HORMONE | | 17126340 |
928 | CD9 | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | | LIF | | 11950938 |
928 | CD9 | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | | HERBIMYCIN A | | 7592610 |